Healthpeak Properties (DOC) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Achieved strong Q2 results, driven by the completed merger with Physicians Realty Trust, expanding the portfolio to 758 properties and realizing $45 million in expected synergies.
Increased 2024 guidance for the second time, supported by leasing outperformance, same-store operations, and accretive buybacks.
Net income rose to $145.9 million ($0.21/share) in Q2 2024, up from $51.8 million ($0.09/share) in Q2 2023.
Enhanced focus on real estate operations, with 70% of staff now directly supporting assets.
Operating environment impacted by higher interest rates, inflation, and capital market volatility.
Financial highlights
Q2 2024 FFO as Adjusted: $0.45/share; AFFO: $0.39/share; Nareit FFO: $0.44/share.
Q2 2024 net income: $145.9 million ($0.21/share); total revenues: $695.5 million.
Total portfolio same-store growth: 4.5% year-over-year.
Outpatient medical same-store growth: 3.1%; lab: 3%; CCRC: 21%.
Net debt to EBITDA at quarter-end: 5.2x; nearly $3 billion in liquidity and $300 million in cash.
Outlook and guidance
Raised 2024 FFO as Adjusted guidance to $1.77–$1.81/share and AFFO to $1.54–$1.58/share.
Increased same-store NOI growth guidance to 2.75%–4.25%.
Management expects cash flows and liquidity to be adequate for the next 12 months.
Expect continued acceleration in lab and outpatient medical segments in the second half of the year.
CCRC growth expected to normalize after strong first half.
Latest events from Healthpeak Properties
- 2026 guidance raised after Janus Living IPO, strong leasing, and robust capital actions.DOC
Q1 20266 May 2026 - All director nominees and proposals were approved with a 91% quorum present.DOC
AGM 20261 May 2026 - Q1 2025 delivered strong earnings growth, robust leasing, and reaffirmed 2025 guidance.DOC
Q1 202530 Apr 2026 - Key votes include board elections, executive pay approval, and auditor ratification for 2026.DOC
Proxy Filing12 Mar 2026 - 2025 saw strong results, board refreshment, and enhanced ESG, with key votes on directors, pay, and auditor.DOC
Proxy Filing12 Mar 2026 - Janus Living IPO and operational efficiencies position Healthpeak for growth in core healthcare real estate.DOC
Citi’s Miami Global Property CEO Conference 20263 Mar 2026 - Janus Living IPO, $600M biotech campus acquisition, and $1B capital recycling drive growth.DOC
Investor presentation3 Mar 2026 - 2026 guidance anticipates a bottom in FFO, with growth expected as lab and senior housing recover.DOC
Q4 20253 Feb 2026 - Merger-driven scale, strong leasing, and robust financials support optimistic growth outlook.DOC
Nareit REIT Week: 2024 Investor Conference31 Jan 2026